BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20250915T171234EDT-8944APikGb@132.216.98.100
DTSTAMP:20250915T211234Z
DESCRIPTION:Mortality analyses in the UK Collaborative Trial of Ovarian Can
 cer Screening (UKCTOCS)\n\nSteven Skates received his undergraduate educat
 ion at the University of Western Australia and his graduate education at t
 he University of Chicago in Statistics. He is an associate professor at Ma
 ssachusetts General Hospital and Harvard Medical School where he is an ear
 ly detection investigator. His research is on developing longitudinal algo
 rithms for early detection of ovarian cancer\, conducting and analyzing sc
 reening trials implementing these algorithms\, and discovery and validatio
 n of early detection ovarian cancer serum biomarkers.\n\n	UKCTOCS is a rand
 omized screening trial of 202\,000 postmenopausal UK women with half the w
 omen screened and half not screened. Half the screened women had an annual
  CA125 test as the primary screen interpreted with the risk of ovarian can
 cer algorithm (ROCA)\, a longitudinal method for personalizing screening t
 ests by detecting significant increases above an individual's CA125 baseli
 ne. The secondary test for women at elevated risk was transvaginal ultraso
 und (TVU). The other half of the women screened had annual TVU as a primar
 y screen. Screening began in 2001 and ended 31 December 2011 with follow-u
 p through 31 December 2014. The primary mortality analysis was a proportio
 nal hazards test with mortality from invasive ovarian cancer as the endpoi
 nt which was not significant (p=0.10). There was a preliminary test for pr
 oportionality of hazards which was not significant. A pre-specified subgro
 up analysis of 80% of the cases (excluding the 20% prevalent cases) was si
 gnificant (p = 0.02) following a significant test for non-proportionality 
 (p=0.03). This subgroup analysis was prespecified because it was expected 
 that ROCA would be less effective when there are no baseline measurements 
 which is equivalent to a prevalent case. Further follow-up through Decembe
 r 2018 is underway with the primary endpoint updated to account for adopti
 on in 2016 of the WHO 2014 pathological definition of ovarian cancer. We w
 ill raise the question of whether the primary statistical analysis should 
 be updated to reflect new statistical insights since the primary analysis 
 was defined in 2001.\n\n \n\n \n
DTSTART:20171003T193000Z
DTEND:20171003T203000Z
LOCATION:Room 521\, McIntyre Medical Building\, CA\, QC\, Montreal\, H3G 1Y
 6\, 3655 promenade Sir William Osler
SUMMARY:Steven J. Skates\, PhD\, Massachusetts General Hospital/Harvard Med
 ical School
URL:/mathstat/channels/event/steven-j-skates-phd-massa
 chusetts-general-hospitalharvard-medical-school-270700
END:VEVENT
END:VCALENDAR